Description

7511-100-k_calculation_worksheet

Trevigen’sGlutathioneAssayutilizesacarefullyoptimizedenzymaticrecyclingmethod,whichemploysGlutathioneReductase,forthequantificationofglutathione.ThesulfhydrylgroupofglutathionereactswithDTNB(5,5’-dithiobis-2-nitrobenzoicacid,Ellman’sreagent)andproducesayellow-colored5-thio-2-nitrobenzoicacid(TNB).Themixeddisulfide,GSTNB(betweenGSHandTNB)thatisconcomitantlyproduced,isreducedbyGlutathioneReductasetorecycletheGSHandproducemoreTNB.TherateofTNBproductionisdirectlyproportionaltotheconcentrationofGSHinthesample.Thus,measurementoftheabsorbanceofTNBat405or412nmprovidesanaccurateestimationoftheamountofglutathioneinthesample.

FEATURES:

• Suitableformammaliancells,tissue,blood,plasmaandotherbodilyfluids.
• Formattedfor96-wellplates.
• Containssufficientreagentstoassay384datapointsortodetermineGSHin:

1. 123experimentalsamples,eachperformedintriplicate,plusoneGSHstandardcurve.
2. 108experimentalsamples,eachperformedintriplicate,plus4GSHstandardcurves.
3. 88experimentalsamples,eachperformedintriplicate,plus8GSHstandardcurves.

• Includesprocedurefordeterminingoxidizedandreducedglutathione.

APPLICATIONS:

Calculatingtotal,reduced,andoxidizedglutathioneconcentrations.

Catalog#7511-100-Kincludes:
CatalogNumber	Description	Qty
7511-100-01	GlutathioneReductase	1
7511-100-02	25XAssayBuffer	1
7511-100-04	ReactionMix	1
7511-100-05	96-WellPlates	1
7511-100-06	4µMGSSG	1

RosiglitazoneCausesCardiotoxicityviaPeroxisomeProliferator-ActivatedReceptorgamma-IndependentMitochondrialOxidativeStressinMouseHearts
HuameiHe,HaiTao,HuiXiong,ShengZhongDuan,FrancisX.McGowan,Jr.,RichardM.Mortensen,andJamesA.Balschi
Toxicol.Sci.,Apr2014;138:468–481.
http://toxsci.oxfordjournals.org/cgi/content/abstract/138/2/468

“Characterizationofac-RelInhibitorThatMediatesAnticancerPropertiesinHematologicMalignanciesbyBlockingNF-B–ControlledOxidativeStressResponses”
“YusukeShono,AndreaZ.Tuckett,Hsiou-ChiLiou,EkaterinaDoubrovina,EnricoDerenzini,SamedyOuk,JenniferJ.Tsai,OdetteM.Smith,EmilyR.Levy,FABIanaM.Kreines,CarlyG.K.Ziegler,MaryI.Scallion,MikhailDoubrovin,GlennHeller,AnasYounes,RichardJ.O’Reilly,MarcelR.M.vandenBrink,andJohannesL.Zakrzewski”
CancerRes.,Jan2016;76:377–389
http://cancerres.aacrjournals.org/cgi/content/abstract/76/2/377

IncreasedVEGF-Apromotesmultipledistinctagingdiseasesoftheeyethroughsharedpathomechanisms
AlexanderGMarneros
EMBOMolMed.,Mar2016;8:208–231.
http://EMBOMolMed.embopress.org/cgi/content/abstract/8/3/208

Trevigen公司位于美国马里兰州的高科技走廊，是一家有12年历史、成长迅速的生物技术公司，其产品和技术的发展方向主要在癌症研究领域，重点强调细胞凋亡、DNA损伤和修复，以及癌症细胞功能和行为。Trevigen品牌的分销商遍及北美，欧洲和环太平洋地区。关于DNA的损伤分析技术的研究，Trevigen获得美国国立卫生研究院（NIH）的SBIR项目资助。